How to buy BioCardia stock

BioCardia, Inc is a biotechnology business based in the US. BioCardia shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. BioCardia employs 24 staff and has a trailing 12-month revenue of around 0.00.

BioCardia share price

Use our graph to track the performance of BCDA stocks over time.

BioCardia shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.91 - $6.50
50-day moving average	$4.07
200-day moving average	$3.54
Wall St. target price	$12.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.20

Buy BioCardia shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BioCardia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioCardia, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCardia financials

Revenue TTM	$145,000
Gross profit TTM	$-9,668,000
Return on assets TTM	-62.41%
Return on equity TTM	-139.27%
Profit margin	0%
Book value	$1.18
Market capitalisation	$59.4 million

TTM: trailing 12 months

Shorting BioCardia shares

There are currently 421,847 BioCardia shares held short by investors – that's known as BioCardia's "short interest". This figure is 8% down from 458,311 last month.

There are a few different ways that this level of interest in shorting BioCardia shares can be evaluated.

BioCardia's "short interest ratio" (SIR)

BioCardia's "short interest ratio" (SIR) is the quantity of BioCardia shares currently shorted divided by the average quantity of BioCardia shares traded daily (recently around 166737.94466403). BioCardia's SIR currently stands at 2.53. In other words for every 100,000 BioCardia shares traded daily on the market, roughly 2530 shares are currently held short.

However BioCardia's short interest can also be evaluated against the total number of BioCardia shares, or, against the total number of tradable BioCardia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCardia's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BioCardia shares in existence, roughly 30 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable BioCardia shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCardia.

Find out more about how you can short BioCardia stock.

BioCardia share dividends

We're not expecting BioCardia to pay a dividend over the next 12 months.

Have BioCardia's shares ever split?

BioCardia's shares were split on a 1:9 basis on 5 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioCardia shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for BioCardia shares which in turn could have impacted BioCardia's share price.

BioCardia share price volatility

Over the last 12 months, BioCardia's shares have ranged in value from as little as $1.91 up to $6.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCardia's is 2.0696. This would suggest that BioCardia's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCardia overview

BioCardia, Inc. , a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California. .

Frequently asked questions

What percentage of BioCardia is owned by insiders or institutions?
Currently 38.722% of BioCardia shares are held by insiders and 11.247% by institutions. How many people work for BioCardia?
Latest data suggests 24 work at BioCardia. When does the fiscal year end for BioCardia?
BioCardia's fiscal year ends in December. Where is BioCardia based?
BioCardia's address is: 125 Shoreway Road, San Carlos, CA, United States, 94070 What is BioCardia's ISIN number?
BioCardia's international securities identification number is: US09060U5074 What is BioCardia's CUSIP number?
BioCardia's Committee on Uniform Securities Identification Procedures number is: 09060U101